Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.

RPEP-089192024Mørk, Sofie Kirial; Skadborg, Signe Koggersbøl; Albieri, Benedetta; Draghi, Arianna; Bol, Kalijn; Kadivar, Mohammad; Westergaard, Marie Christine Wulff; Stoltenborg Granhøj, Joachim; Borch, Annie; Petersen, Nadia Viborg; Thuesen, Nikolas; Rasmussen, Ida Svahn; Andreasen, Lars Vibe; Dohn, Rebecca Bach; Yde, Christina Westmose; Noergaard, Nis; Lorentzen, Torben; Soerensen, Anders Bundgaard; Kleine-Kohlbrecher, Daniela; Jespersen, Anders; Christensen, Dennis; Kringelum, Jens; Donia, Marco; Hadrup, Sine Reker; Marie Svane, Inge

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.

Journal for immunotherapy of cancer, 12(5)

View on PubMed ↗Publisher’s paper ↗

Citation

Mørk, Sofie Kirial; Skadborg, Signe Koggersbøl; Albieri, Benedetta; Draghi, Arianna; Bol, Kalijn; Kadivar, Mohammad; Westergaard, Marie Christine Wulff; Stoltenborg Granhøj, Joachim; Borch, Annie; Petersen, Nadia Viborg; Thuesen, Nikolas; Rasmussen, Ida Svahn; Andreasen, Lars Vibe; Dohn, Rebecca Bach; Yde, Christina Westmose; Noergaard, Nis; Lorentzen, Torben; Soerensen, Anders Bundgaard; Kleine-Kohlbrecher, Daniela; Jespersen, Anders; Christensen, Dennis; Kringelum, Jens; Donia, Marco; Hadrup, Sine Reker; Marie Svane, Inge. (2024). Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.. Journal for immunotherapy of cancer, 12(5). https://doi.org/10.1136/jitc-2024-008817